STRATEC SE

Earnings Release • Apr 26, 2007

News Details

Ad-hoc | 26 April 2007 14:28

STRATEC achieves further sales and earnings growth in the first quarter of

STRATEC Biomedical Systems AG / Quarter Results/Preliminary Results

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC achieves further sales and earnings growth in the first quarter of
2007

Birkenfeld, April 26, 2007

The Board of Management of STRATEC Biomedical Systems AG, which is listed
in the Prime Standard, hereby announces the preliminary unaudited
consolidated figures of the consolidated STRATEC Group for the first
quarter of the 2007 financial year as of March 31, 2007 pursuant to IFRS
(International Financial Reporting Standards) and in accordance with
Section 15 of the German Securities Trading Act (WpHG).

Key Figures (EUR 000s) 01.01.- 03.31.2007 01.01.- 03.31.2006 Change
Sales 15,674 15,359 + 2.1%
Gross performance 16,131 15,258 + 5.7%
EBITDA 3,055 2,424 + 26.0%
EBIT 2,531 2,154 + 17.5%
EBT 2,560 2,138 + 19.7%
Consolidated net income 1,949 1,572 + 24.0%
Earnings per share (EUR) 0.17 0.14 + 21.4%

The consolidated STRATEC Group had a total workforce of 246, including
personnel provided by a temporary employment agency, as of March 31, 2007
(previous year: 206).

---

Information and Explaination of the Issuer to this News:

Based on current planning, the growth forecast for the consolidated Group
will be reflected in particular in the second half of the 2007 financial
year.

The extensive interim report will be available for downloading from our
internet site from around 3.00 p.m. on May 9, 2007.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories and research
institutes around the world. The company develops its products on the basis
of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-mail: ir@stratec-biomedical.de

DGAP 26.04.2007

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
www: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---